Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More

Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
Biogen, a global biotechnology company renowned for its pioneering work in neuroscience, has announced a significant strategic acquisition of Apellis…
Read More